Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (27225)	1/6/1999 10:40:00 AM
From: Machaon	Read Replies (4) \| Respond to of 32384

<< Maybe you need to take a basic Finance & Accounting Course before you try to inflict your knowledge or lack of it on this thread. >> Thanks for the advice. <g> I don't know about everyone else, but when I read an earnings report I look for cash on hand, the President's explanations of important events, earnings related data and any clinical announcements. I still say that you are wrong that "cash on hand" is not an important part of the earnings report. But, who cares. If you ignore cash on hand when you look at an earnings report, so be it! Of course, if one really wants detail, you need to go to the 10Q or 10K, where you can also read about managements views and projections, and future cash requirements. About inflicting knowledge on this thread, how about responding to the following repeat of my earlier questions, if you can? "I've got an idea. How about you taking the high road, for a change, and contributing to this thread instead of posting insults and provoking others. What's your prediction for Ligand in the short term and the long term. Are you still a naysayer? Do you have any reason to still be a naysayer? One of the recent analysts has a price target of $30 for Ligand. Any thoughts on that?"